Designing and Comparison of Two Types of Chitosan Nanogels for Doxorubicine Delivery

Drug delivery systems related to different cancer therapy is now expanding. Chitosan (CS) is currently receiving enormous interest for medical and pharmaceutical applications due to its biocompatibility in animal tissues. In this study two nanogels were prepared from Chitosan. Some of the critical factors such as controlling the release, adsorption and specially targeting drug delivery are considered while preparing the nanogels. Phosphorylated chitosan (PCS) and Myristilated chitosan (MCS)nanogeles were prepared by reacting Chitosan with tripolyphosphate (TPP) and Myristate as a cross linking agents respectively and then were loaded with Doxorubicin (DOX). The Nanogels were characterized by different techniques such as Scaning Electron Microscopy, Dynamic Light Scattering and Fourier-transform infrared. The cytotoxicity of free DOX, MCS nanogels and DOX loaded MCS were evaluated by MTT assay. The results of DOX loading and releasing of the nanogels showed high loading capacity and drug loading efficiency of about 97%. Results indicated slow release of about 16-28% of DOX from PCS within 5 days and 18-40% from MCS within 15 days. The DOX and MCS-DOX showed the same toxic effect on the prostate cancer cells (LNCaP). Both PCS and MCS nanogels were qualified on the base of size, loading and releasing capacity.